Sure, but we haven't even got thru the FDA. This result will only enhance the case of a successful FDA outcome, it won't change anything at the clinical/patient level.
In the world of biotech and medical devices though, this outcome should be significantly value accretive, that is, the technology will be worth a whole lot more on a succesful trial.
How much more, who knows? But you'd be a bit disappointed if it didn't punch thru the IPO price.
General Investor Information EBR Systems, page-42
-
- There are more pages in this discussion • 301 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add EBR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
95.0¢ |
Change
-0.030(3.06%) |
Mkt cap ! $292.7M | |||
| Open | High | Low | Value | Volume |
| 98.0¢ | 98.5¢ | 94.5¢ | $213.8K | 222.8K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 3956 | 94.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 95.0¢ | 151 | 3 |
View Market Depth
| Last trade - 16.10pm 13/09/2024 (20 minute delay) ? |
| EBR (ASX) Chart |